Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 13/20 | 0.57 |
| ▸ | P2RY6 | Q15077 | 7/20 | 0.57 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.53 |
| ▸ | P2RY14 | Q15391 | 4/20 | 0.53 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.52 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.52 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.52 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2800171 | 0.91 | P2RY2 (0.61) | P2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL18770063 | 0.90 | P2RY2 (0.62) | P2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL607048 | 0.90 | P2RY2 (0.62) | P2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL11688923 | 0.87 | P2RY2 (0.53) | P2RY2P2RY6P2RY4P2RY14SLC28A1 | |
| SCHEMBL18007470 | 0.86 | P2RY2 (0.57) | P2RY2P2RY6P2RY4P2RY14SLC28A1 | |
| SCHEMBL15643790 | 0.85 | SLC28A1 (0.55) | P2RY2P2RY6P2RY4P2RY14SLC28A1 | |
| SCHEMBL15643275 | 0.85 | SLC28A1 (0.55) | P2RY2P2RY6P2RY4P2RY14SLC28A1 | |
| SCHEMBL1704984 | 0.84 | P2RY2 (0.54) | P2RY2P2RY6P2RY4P2RY14SLC28A1 | |
| Phosphoric Acid SCHEMBL9576797 | 0.83 | P2RY2 (0.53) | P2RY2P2RY6P2RY4P2RY14SLC28A1 | |
| SCHEMBL1585708 | 0.82 | SLC28A1 (0.60) | P2RY2P2RY6P2RY4P2RY14SLC28A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12357617-B2 | Discovery of novel anti-infectives for gram negative pathogens | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-07-15 | — | — | US | disclosed |
| US-12325859-B2 | Microbial approach for the production of long chain compounds | UT-BATTELLE, LLC (US) | 2025-06-10 | — | — | US | disclosed |
| CN-114206896-B | Cyclic deoxyribonucleotide compounds | 纽科利制药公司 | 2024-12-17 | — | — | CN | disclosed |
| EP-3538151-B1 | HUMAN PLASMA-LIKE MEDIUM | WHITEHEAD INST BIOMEDICAL RES (US) | 2024-06-26 | — | — | EP | disclosed |
| CN-117563014-A | Antibody-drug gene conjugate and application thereof | 上海交通大学 | 2024-02-20 | — | — | CN | disclosed |
| EP-3250693-B2 | PROTEIN DELIVERY IN PRIMARY HEMATOPOIETIC CELLS | UNIV CALIFORNIA (US) | 2023-12-20 | — | — | EP | disclosed |
| US-20230056452-A1 | MICROBIAL APPROACH FOR THE PRODUCTION OF LONG CHAIN COMPOUNDS | U.S. DEPARTMENT OF ENERGY | 2023-02-23 | — | — | US | disclosed |
| US-20230051644-A1 | HUMAN PLASMA-LIKE MEDIUM | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH | 2023-02-16 | — | — | US | disclosed |
| WO-2023018718-A1 | MICROBIAL APPROACH FOR THE PRODUCTION OF LONG CHAIN COMPOUNDS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| US-11453858-B2 | Human plasma-like medium | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2022-09-27 | — | — | US | disclosed |
| EP-1100964-A1 | GENE SEQUENCE VARIANCES WITH UTILITY IN DETERMINING THE TREATMENT OF DISEASE | Variagenics, Inc. (US) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000004194-A1 | GENE SEQUENCE VARIANCES WITH UTILITY IN DETERMINING THE TREATMENT OF DISEASE | VARIAGENICS, INC. (US) | 2000-01-27 | — | — | WO | disclosed |
| US-5968914-A | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides | PRO-NEURON, INC. (US) | 1999-10-19 | — | — | US | disclosed |
| US-5859295-A | Canavanine analogs and their use as chemotherapeutic agents | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 1999-01-12 | — | — | US | disclosed |
| EP-0831849-A1 | METHODS OF REDUCING TOXICITY OF CHEMOTHERAPEUTIC AND ANTIVIRAL AGENTS WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996040165-A1 | METHODS OF REDUCING TOXICITY OF CHEMOTHERAPEUTIC AND ANTIVIRAL AGENTS WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0746336-A1 | PRODRUGS ACTIVATED BY TARGETED CATALYTIC PROTEINS | IGEN, INC. (US) | 1996-12-11 | — | — | EP | disclosed |
| US-5552440-A | Use of L-canavanine as a chemotherapeutic agent for the treatment of pancreatic cancer | THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 1996-09-03 | — | — | US | disclosed |
| EP-0746336-A4 | PRODRUGS ACTIVATED BY TARGETED CATALYTIC PROTEINS | IGEN INC (US) | 1996-07-26 | — | — | EP | disclosed |
| WO-1993002703-A1 | PRODRUGS ACTIVATED BY TARGETED CATALYTIC PROTEINS | IGEN, INC. (US) | 1993-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12357617-B2 | Discovery of novel anti-infectives for gram negative pathogens | BET1, BOLA2; BOLA2B, BRD2 | P2RY2 2202/4885P2RY6 3919/4885P2RY4 3264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.